These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22674760)

  • 1. The effect of differing pharmacologic strategies on infarct size in primary PCI--more confirmatory data for bivalirudin.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1090-1. PubMed ID: 22674760
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy in PCI: why not heparin?
    Shahzad A; Cooper RM; Stables RH
    EuroIntervention; 2013 Aug; 9(4):423-6. PubMed ID: 23965346
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
    Di Sciascio G; Mangiacapra F
    J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
    Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
    EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin in acute myocardial infarction: "primum non nocere": the eternal dilemma: balancing risks and benefits in high-risk patients.
    Alfonso F; Paulo M
    JACC Cardiovasc Interv; 2010 Aug; 3(8):803-5. PubMed ID: 20723850
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction.
    Mehilli J; Neumann FJ; Ndrepepa G; King L; Schulz S; Maimer Rodrigues da Cunha F; Jochheim D; Byrne RA; Hausleiter J; Ott I; Massberg S; Kastrati A; Pache J
    Am Heart J; 2013 Apr; 165(4):537-43. PubMed ID: 23537970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
    EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin.
    White HD
    Am Heart J; 2002 Feb; 143(2):189-92. PubMed ID: 11835018
    [No Abstract]   [Full Text] [Related]  

  • 14. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
    Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
    N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failed thrombolysis in myocardial infarction.
    Qasim A; Chauhan A; More RS
    Int J Cardiol; 2000 Aug; 75(1):5-14. PubMed ID: 11054500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.
    Gibson CM; Maehara A; Lansky AJ; Wohrle J; Stuckey T; Dave R; Cox D; Grines C; Dudek D; Steg G; Parise H; Wolff SD; Cristea E; Stone GW
    Am Heart J; 2011 Mar; 161(3):478-486.e7. PubMed ID: 21392601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy to support primary PCI.
    Morrow DA
    N Engl J Med; 2008 May; 358(21):2280-2. PubMed ID: 18499573
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prehospital treatment of patients with acute myocardial infarction with bivalirudin.
    Hirschl MM; Mayr H; Erhart F; Brunner W; Steger F; Gattermeier M; Pfeffel F
    Am J Emerg Med; 2012 Jan; 30(1):12-7. PubMed ID: 20971597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.